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bjectives This study was designed to investigate whether endothelial dysfunction is related to
rug-eluting stent (DES) implantation at 6 months after stenting.
ackground Current available DES could delay vessel healing and subsequently impair endothelial
unction.
ethods Endothelial function was estimated at 6-month follow-up in 75 patients (31 men, mean
ge 62.1 years) with a DES (39 sirolimus-eluting stents [SES], 36 paclitaxel-eluting stents [PES]), and
0 patients with a bare-metal stent (BMS) to the left anterior descending artery, by incremental ace-
ylcholine (Ach) infusion (20 g/min, 50 g/min, 100 g/min) and nitrate (200 g/min) into the left
oronary ostium. Vascular responses were quantitatively measured in arterial segments 5 mm proxi-
al and distal to DES and compared with corresponding segments in the BMS group and midseg-
ents in the left circumﬂex artery as a reference nonstented artery. All antianginal agents were
ithheld for at least 72 h before coronary angiography.
esults Greater vasoconstriction to Ach was observed in both the SES and PES groups than in the
MS group or control segments of left circumﬂex artery. Vasoconstriction to Ach was more promi-
ent in arterial segments distal to stents in both SES and PES groups compared with those in the
MS group (p  0.001). The degree of vasoconstriction to Ach was similar between the SES and PES
roups. Endothelium-independent vasodilatation to nitrate did not differ signiﬁcantly between the
tudy groups.
onclusions Abnormal vasoconstriction to Ach was found in the SES and PES groups, especially in
rterial segments distal to DES at 6 months after stenting, which suggests that DES has a potential
ong-term adverse effect on local coronary endothelial dysfunction. (J Am Coll Cardiol Intv 2008;1:
5–71) © 2008 by the American College of Cardiology Foundation
rom the Cardiovascular Center, Korea University, Guro Hospital, Seoul, Republic of Korea. This study was supported by a
pecial Research Grant from Korea University, Seoul (to Dr. Kim).anuscript received August 1, 2007; revised manuscript received October 19, 2007, accepted November 15, 2007.
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66rug-eluting stents (DES), a polymer-based sirolimus or
aclitaxel local delivery system from a stent platform, have
ignificantly reduced the occurrence of restenosis (1). However,
rst-generation DES introduced new problems, such as de-
ayed vessel healing and endothelial dysfunction, and in vitro
tudies have shown that endothelial function in swine coronary
egments incubated with sirolimus is severely impaired (2).
See page 72
ecent data obtained in human studies showed that
irolimus-eluting stents (SES) can impair endothelial func-
ion over a period of 6 months post-implantation (3,4).
ore recently, Obata et al. (5) showed that sirolimus was
ignificantly detected in the coronary circulation at 2 weeks
fter SES implantation and the levels of vascular endothelial
rowth factor (VEGF), the expression of which could be
educed by sirolimus in vitro (6), was lower in the anterior
nterventricular vein than in the aortic root. Based on these
ndings, coating drugs released from DES into the coronary
flow could affect the endothelial
function in the stented artery
selectively.
In view of the antiproliferative
effect of paclitaxel, paclitaxel-
eluting stents (PES) could also be
associated with endothelial dys-
function. However, although the
suggestion that PES are associ-
ated with endothelial dysfunction
has been made in some reports
(7,8), data concerning the effects
of PES on coronary endothelial
function are lacking. Therefore, in
he present study, we investigated whether SES or PES
mplantation is related to coronary endothelial-dependent and
ndothelial-independent function at 6 months after DES
mplantation.
ethods
atients. From March 2002 to March 2007, 75 DES
atients (39 Cypher SES [Johnson & Johnson, New Bruns-
ick, New Jersey], 36 Taxus PES [Boston Scientific,
atick, Massachusetts]) and 10 Driver (Medtronic, Min-
eapolis, Minnesota) cobalt-based bare-metal stent (BMS)
atients who were treated with a single DES for a de novo
ingle lesion of the left anterior descending artery under-
ent coronary angiography and endothelial function testing
t 6-month follow-up. Intravascular ultrasound-guided
tenting was performed in 9 SES patients (23%) and 4 PES
atients (11%). All patients were prospectively recruited at
he Department of Cardiology of the Guro Hospital, Korea
bbreviations
nd Acronyms
ch  acetylcholine
NOVA  analysis of
ariance
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)niversity, Seoul. Patients with a 50% stenotic lesion sxcept for culprit lesion, a history of acute coronary syn-
rome or coronary spasm (transient ST-segment elevation
t rest with chest pain), symptomatic congestive heart
ailure, left ventricular dysfunction (ejection fraction
30%), in-stent or in-segment restenosis (30%, reference
iameters 2.5 mm or 4.0 mm, respectively), underlying
tructural heart disease or other serious medical conditions
ere excluded. Assessments of conventional cardiovascular
isk factors were performed in all cases. All patients received
spirin, clopidogrel, and/or cilostazol as an antiplatelet
egimen. Unfractionated heparin (50 IU/kg) was given
uring percutaneous coronary intervention, and glyco-
rotein IIb/IIIa inhibitors were used at the physician’s
iscretion. This study was approved by the institutional
eview board of Korea University. Written informed con-
ent was obtained from all patients before study entry.
valuation of endothelial function. All antianginal agents
ere withheld for at least 72 h before coronary angiography.
nd-diastolic images for each segment were chosen accord-
ng to the corresponding points on the electrocardiogram
race and analyzed using the proprietary quantitative coro-
ary angiographic system for the catheterization laboratory
nd an automated edge detection program (BH-3000,
hilips, Best, the Netherlands). Simultaneous biplane pro-
ections were acquired in all patients. Two orthogonal views
ith less foreshortening or without overlapping of side
ranches were selected and averaged for biplane assessment
y 2 blinded expert observers.
Endothelial function tests were performed by infusing
ncremental doses of acetylcholine (Ach) into the left
oronary artery through the Judkins catheter (20 g, 50 g,
nd 100 g for 1 min, performed at an infusion rate of 5
l/min); a 5-min interval was allowed between doses.
hen the maximum tolerable dose was reached, intracoro-
ary bolus injection of nitroglycerin (200 g) was adminis-
ered. Angiography was repeated after each dose of Ach,
nd within 2 min of nitrate administration. Infusions were
topped if severe coronary artery constriction occurred at
ny Ach dose. Two segments in each study vessel, that is, 5
m proximal and distal to sites of stenting, were chosen for
nalysis. These segments were chosen regardless of their
ascular responses and were in all cases at sites without
ngiographically evident disease. For comparison with nor-
al response to Ach, the vasomotor reactivity to Ach and
itrate infusion was estimated in the midsegment of non-
tented, left circumflex artery. The pre- and adjunctive
ost-balloon was applied to a shorter area than stent
ength to avoid areas subject to balloon injury. Changes
n coronary diameter in response to Ach and nitrate
oronary infusion were expressed as percent changes
ersus baseline angiograms.
Interobserver and intraobserver variability for repeated
easurements of quantitative coronary angiography in the
ame recordings of 20 randomly selected patients were
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67.060  0.03 mm and 0.020  0.02 mm, respectively.
uring the procedure, blood pressure via guiding catheter
nd heart rate were continuously monitored.
tatistical analysis. All data are reported as means  stan-
ard deviation. Group demographic data were compared
sing a 1-way analysis of variance (ANOVA) with a Scheffe
est for multiple comparisons for continuous variables, or
ruskal-Wallis ANOVA on ranks followed by the Dunn
est for categorical variables. Changes in coronary diameters
n response to drug infusions were compared between
roups using ANOVA for repeated measurements and
ollowed by post-hoc testing with a Scheffe test for multiple
omparisons whenever the general test was significant.
inary variables were analyzed by the Fisher exact test.
hanges in mean luminal diameter to maximal Ach dose
ere compared using 1-way ANOVA with post-hoc
Scheffe) test. For within-group comparisons such as
hanges in proximal versus distal sites, the paired Student t
est was used. Statistical significance was accepted at p 0.05.
ommercially available computer software (SPSS version 11.0,
PSS Inc., Chicago, Illinois) was used for all analyses.
esults
he baseline characteristics of the 75 DES (56 men, mean
ge 54.7 years), and 10 BMS (6 men, mean age 60.7 years)
atients are shown in Table 1. A total of 39 SES and 36
ES patients were enrolled. There were no differences in
ge, gender, left ventricular function, hemodynamic vari-
bles, or risk factors among the SES, PES, and BMS groups
Table 1).
Table 1. Baseline Clinical Characteristics
SES (n  39)
Age, yrs 63.0  9.5
Gender (male, %) 22 (56.4)
EF (%) 51.4  8.1
Systolic blood pressure (mm Hg) 134  14
Diastolic blood pressure (mm Hg) 86  12
Heart rate (beats/min) 78  5
Underlying disease
HTN 16 (41.0)
DM 7 (17.9)
Smoking 8 (20.5)
Obesity (BMI 25 kg/m2) 7 (17.9)
Hyperlipidemia 8 (20.5)
Family history of CVD 13 (33.3)
Medications
Statin 25 (64.1)
ARB/ACEI 12 (30.7)
*The p values relate to differences between the 3 groups of patients using analysis of variance: 1) S
ARB/ACEI angiotensin receptor blocker/angiotensin-converting enzyme inhibitor; BMI bodyfraction; HTN hypertension; PES paclitaxel-eluting stent; SES sirolimus-eluting stent.ngiographic analysis—endothelial dysfunction in the DES
nd BMS groups. No differences were observed between the
ES, SES, and BMS groups in terms of reference segment
iameter proximal and distal to the stents (Table 2). The
roportions of subjects that achieved a maximal Ach dose
ere similar among the SES, PES, and BMS groups (84.4%
s. 82.3% vs. 100%, respectively).
Figure 1 shows the typical vasoreactivity in response to
ch infusion in the segments to DES compared with that of
MS or corresponding segments of the left circumflex
rtery as a reference nonstented artery. After incremental
ch infusion, sites proximal to DES showed a trend toward
ntense vasoconstriction compared with the BMS group
18.8  13.6, 14.4  11.9 vs. 3.89  6.79; 21.5 
4.9, 19.2  13.9 vs. 5.88  9.90; 24.3  15.6,
23.2  15.7 vs. 6.31  9.63; SES, PES vs. BMS, p 
.14, p  0.11, p  0.08, respectively) (Fig. 2, Table 2). As
or sites distal to stents, more significant vasoconstriction
ccurred in the DES group than in the BMS group (53.6
14.9, 48.4  11.9 vs. 6.70  5.10; 63.1  16.1,
54.4  13.9 vs. 5.88  14.4; 72.9  11.6, 71.8 
5.7 vs.7.91 20.4; SES, PES vs. BMS, p 0.001, p
.001, p  0.001 respectively) (Fig. 2, Table 2). The
asomotor reactivity in response to Ach infusion of the left
ircumflex artery as a reference artery was similar between
he SES, PES, and BMS groups (Fig. 2).
ngiographic analysis—endothelial dysfunction in the SES
nd PES groups. Mean stent diameter and length were not
ignificantly different between the SES and PES groups
Table 2). Regarding vasomotor response to Ach infusion,
ignificant vasoconstrictions to maximal Ach infusion were
PES (n  36) BMS (n  10) p Value*
63.2  10.3 60.7  8.8 0.68
19 (52.8) 6 (60.0) 0.55
50.3  7.9 52.3  6.18 0.67
129  12 128  14 0.54
82  9 78  10 0.59
82  4 84  6 0.57
15 (41.6) 5 (50.0) 0.56
7 (19.4) 2 (20.0) 0.43
9 (25.0) 2 (20.0) 0.52
9 (25.0) 2 (20.0) 0.46
8 (22.2) 3 (30.0) 0.33
11 (30.5) 2 (20.0) 0.37
23 (63.8) 7 (58.3) 0.47
9 (25.0) 4 (33.3) 0.38
p; 2) PES group; 3) BMS group.
dex; BMS bare-metal stent; CVD cardiovascular disease; DM diabetesmellitus; EF ejectionES grou
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68bserved in segments proximal and distal to stents (Fig. 3,
able 2). After incremental Ach infusion, mean coronary
iameter changes were similar between SES and PES
roups (proximal sites: p  0.52, p  0.74, p  0.81; distal
ites: p  0.72, p  0.60, p  0.92; A1, A2, A3
espectively) (Fig. 2). Changes in mean luminal diameter in
esponse to Ach were greater at sites distal to than at sites
roximal to stents in both the SES and PES groups (p 
.001) (Figs. 2 and 3, Table 2).
asoreactivity in response to nitrate infusion. The DES and
MS groups showed no differences of vasodilation in
esponse to nitrate infusion (Table 2). There were no
ignificant differences of vasodilation between sites proximal
nd distal to stents (p  0.56) (Table 2).
iscussion
n the present study, the SES and PES groups showed
reater vasoconstriction of DES-implanted arteries in re-
ponse to Ach coronary infusion than the BMS group at
orresponding segments. Vasoconstriction to Ach was more
rominent in arterial segments distal to DES than in
roximal segments in both SES and PES groups, but
egrees of vasoconstriction to Ach were similar between
hese groups. Endothelium-independent vasodilatation to
itrate in the DES group and control subjects did not differ
ignificantly. To the best of our knowledge, this is the first
ublished comparison of SES and PES on long-term
Table 2. Comparison of the Angiographic Changes Among SES, PES, and B
SES (n  39)
Lesion characteristics
Diameter stenosis, % 80.3 4.5
Lesion length, mm 20.5 6.6
Mean stent length, mm 23.3 6.0
Stent deployment pressure, mm Hg 13.8 1.1
Mean stent diameter 2.96 0.33
Proximal to stent
Reference diameter, mm 3.08 0.11
Diameter change to maximal Ach, mm 0.56 0.73
Diameter change to maximal Ach, % 24.7 16.8
Diameter change to nitrate, mm 0.42 0.48
Diameter change to nitrate, % 13.2 13.6
Distal to stent
Reference diameter, mm 2.90 0.48
Diameter change to maximal Ach, mm 2.08 0.18
Diameter change to maximal Ach, % 70.9 11.5
Diameter change to nitrate, mm 0.55 0.52
Diameter change to nitrate, % 18.6 17.8
*The p values relate to differences between the 3 groups of patients using analysis of variance: 1) S
Ach acetylcholine; other abbreviations as in Table 1.ndothelial dysfunction. (The advent of DES has drastically reduced angio-
raphic restenosis rates as compared with those of BMS
1). However, despite these considerable benefits, issues
elated to the safety of DES have attracted increasing
ttention. Moreover, clinical data and some experimental
bservations have led to speculation that endothelial
mpairment and delayed healing might compromise DES
afety (4). Endothelial dysfunction is associated with the
oss of endothelial vasoprotective factors, such as nitric
xide, and possibly subsequent coronary vasoconstriction
9). Acetylcholine may dilate coronary arteries with intact
ndothelium by inducing the release of nitric oxide, al-
hough paradoxically, it constricts vessels when endothelium
s damaged (10). Furthermore, endothelial dysfunction is
ssociated with a thrombogenic vascular milieu because of
he absences of various substances that promote endothelial
urvival and proliferation and inhibit platelet aggregation,
eukocyte infiltration, and vascular smooth muscle cell
roliferation.
Rapamycin and paclitaxel equally suppress endothelial
ell proliferation, and consequently impair endothelial func-
ion in vitro (2). Experimentally, more than 80% of the
apamycin in SES is eluted at 28 days post-implantation
nd almost all at 60 days, whereas paclitaxel in PES showed
iphasic kinetics with an initial burst during the first 48 h
fter stent implantation followed by a slow low-level release
ver at least 2 weeks (11). A previous preclinical study
howed that both SES and PES showed normal vascular
ealing at 1 month, and endothelial function was recovered
PES (n  36) BMS (n  10) p Value*
76.8 3.9 75.9 6.6 0.78
21.1 7.2 18.2 5.2 0.67
24.6 6.8 23.3 8.3 0.73
13.1 1.4 13.1 1.4 0.75
2.80 0.37 3.06 0.34 0.36
2.80 0.37 3.16 0.31 0.42
0.47 0.64 0.12 0.26 0.11
23.4 15.7 6.23 8.49 0.09
0.62 0.53 0.51 0.47 0.29
20.2 18.3 14.05 13.8 0.33
2.54 0.64 2.60 0.33 0.15
1.75 0.12 0.47 0.23 0.004
68.7 12.1 21.6 4.04 0.001
0.84 0.80 0.56 0.48 0.24
23.2 27.8 17.21 15.12 0.21
p; 2) PES group; 3) BMS group.MS
ES grou12). However, recent reports have raised concerns that late
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69tent thrombosis is steady, with no evidence of diminution
fter 3 years of follow-up for SES and PES (13). A
orphologic autopsy study showed delayed arterial healing
nd poor re-endothelialization after DES as compared with
MS over similar durations (14). Considering the anti-
hrombotic role of endothelial cells, endothelial dysfunction
fter DES implantation might follow a more protracted
ourse in humans than in animals. Although human data
egarding the effects of SES and PES on endothelial
egeneration are lacking, some case reports have described
ife-threatening coronary artery spasm after SES or PES
mplantation (7,15). Recently, Hofma et al. (3) showed that
ES implantation is associated with endothelial-dependent
asomotor responses in segments distal to SES compared
ith BMS 6 months after stent implantation. Togni et al.
16) described a similar phenomenon, namely, exercise-
nduced paradoxical vasoconstriction of segments adjacent
o SES. However, specific information on PES is lacking. A
ore recent study by Togni et al. (8) showed paradoxical
Figure 1. Examples of Coronary Angiogram With Endothelial Function Test
Coronary angiogram showed a marked vasoconstriction to incremental acetylc
(upper panel) and paclitaxel-eluting stent (PES) (middle panel) compared wit
circumﬂex artery as a reference nonstented artery.asoconstriction during exercise in the persistent region to phe PES. In the present study, the intense vasoconstrictions
o Ach were observed equally for PES and SES as compared
ith those of BMS. In contrast to animal data, it is
ncertain why endothelial dysfunction remains unchanged
t 6 months after DES implantation. Despite a lack of data
rom animal studies, differences in endothelial healing
etween animals and humans could be caused by the
ifferent growth characteristics of their endothelial cells, as
as suggested by Kipshidze et al. (17). Both rapamycin and
aclitaxel are hydrophobic, and therefore they can easily
enetrate vessel walls, which leads to longer drug retention
n arterial tissues (18). In line with previous reports, our data
how that vasoconstriction to Ach is more prominent in
rterial segments distal to rather than proximal to DES in
oth SES and PES groups. Serry and Penny (19) suggested
hat a loaded drug may diffuse into the vasa vasorum and
onsequently influence distal dysfunction. This tentative
xplanation remains to be elucidated.
In terms of possible confounding factors related to the
onths After Stent Implantation
infusion, in particular in the segment distal to sirolimus-eluting stent (SES)
se of bare-metal stent (BMS) (lower panel) or midsegments of the leftat 6 M
holine
h thorocedure, high-pressure ballooning with noncompliant
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descending coronary artery; other abbreviations as in Figure 1.
PES; hatched bars  BMS. Abbreviations as in Figures 1 and 2.
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70alloons could have caused arterial wall injury and affected
ndothelial function. In the present study, pre-ballooning
as performed in all cases and adjunctive ballooning in 75%
f cases. However, the balloons used were shorter than the
tents, and thus, balloon injury at distal or proximal sites
djacent to stent segments was minimized.
Despite strong evidence of delayed endothelial dysfunc-
ion associated with DES implantation, it is unclear how
ong it takes for endothelial function to recover completely.
ecently, Togni et al. (8) showed that exercise-induced
asoconstriction adjacent to PES could change and even
isappear with time, despite temporal differences between
he recoveries of segments proximal and distal to PES. In
he future, further study will be required to clarify this issue.
n addition, further investigation regarding the relationship
etween endothelial dysfunction and its contribution to overall
ES results including late thrombosis will be warranted.
tudy limitations. Several important limitations of this
tudy should be mentioned. First, we could not perform a
re-interventional endothelial function test, and therefore,
ndividual variations in endothelial function may have in-
uenced our results. Second, intravascular ultrasound was
vailable in only some DES patients, and therefore the
ffects of plaque burden or angiographically undetected edge
issection on coronary endothelial function could not be
ompletely excluded (20). Finally, the degree of vasocon-
triction observed in the present study was more pro-
in Response to Incremental Ach and Nitrate Infusion at 6 Months After
than in the BMS group or corresponding segments of the left
similar in the SES and PES groups. Ach  acetylcholine; LAD  left anteriorFigure 2. Comparative Analysis of Mean Percent Changes of Coronary Diameter
Stent Implantation
Sites proximal and distal to DES showed a greater vasoconstriction in the DES group
circumﬂex artery (LCX) as a reference artery. Mean coronary diameter changes wereFigure 3. Comparative Analysis of Mean Percent Changes of
Coronary Diameter in Response to Maximal Ach at 6 Months After
Stent Implantation
Signiﬁcant vasoconstrictions to maximal Ach infusion were observed in the
segments distal to DES compared with those of BMS. Mean coronary diam-
eter changes were similar between SES and PES. Changes in mean luminal
diameter in response to Ach were greater at distal than proximal sites to
stents in both the SES and PES groups. Open bars  SES; solid bars ounced than that described in previous studies. The effects
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71f Ach on coronary endothelial function are known to be
ependent on ethnicity, and Asians show a higher degree of
oronary vasoconstriction in response to Ach infusion than
aucasians (21,22). All subjects enrolled in the present
tudy were Koreans, and thus further work is required to
scertain differences in coronary endothelial response to Ach
n DES patients by race. To overcome the previously
entioned limitations and answer previously cited ques-
ions, a well-designed comparative prospective study on pre-
nd post-intervention endothelial function for DES versus
MS should be considered. In addition, to clarify the
linical relevance of DES-related endothelial dysfunction,
ong-term follow-up is required.
onclusions
his study provides in vivo evidence that both SES and PES
an impair endothelial function and that their effects are
emonstrably present at 6 months after implantation, espe-
ially in arterial segments distal to DES at 6 months
ost-stenting. Our results suggest that DES have long-term
dverse effects on local coronary endothelial function. In
ddition, clinicians should be concerned about the potential
isk of spasm after DES implantation in relation to endo-
helial dysfunction (4,12).
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